Beskow Laura M
Program for Empirical Bioethics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27705; email:
Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710.
Annu Rev Genomics Hum Genet. 2016 Aug 31;17:395-417. doi: 10.1146/annurev-genom-083115-022536. Epub 2016 Mar 3.
Human biospecimens have played a crucial role in scientific and medical advances. Although the ethical and policy issues associated with biospecimen research have long been the subject of scholarly debate, the story of Henrietta Lacks, her family, and the creation of HeLa cells captured the attention of a much broader audience. The story has been a catalyst for policy change, including major regulatory changes proposed in the United States surrounding informed consent. These proposals are premised in part on public opinion data, necessitating a closer look at what such data tell us. The development of biospecimen policy should be informed by many considerations-one of which is public input, robustly gathered, on acceptable approaches that optimize shared interests, including access for all to the benefits of research. There is a need for consent approaches that are guided by realistic aspirations and a balanced view of autonomy within an expanded ethical framework.
人类生物样本在科学和医学进步中发挥了关键作用。尽管与生物样本研究相关的伦理和政策问题长期以来一直是学术辩论的主题,但海瑞塔·拉克斯、她的家人以及海拉细胞的诞生故事吸引了更广泛受众的关注。这个故事成为了政策变革的催化剂,包括美国围绕知情同意提出的重大监管变革。这些提议部分基于民意数据,因此有必要更仔细地审视这些数据告诉了我们什么。生物样本政策的制定应考虑诸多因素,其中之一是广泛收集公众对优化共同利益(包括让所有人都能从研究中受益)的可接受方法的意见。需要有以现实期望为指导、在扩展的伦理框架内对自主性持平衡观点的同意方法。